Both AP-1 and NF-kappaB seem to be involved in tumour growth in an experimental rat hepatoma.

Abstract

Daily treatment of rats bearing Yoshida AH-130 ascites hepatoma with the nuclear factor kappa-B (NF-kappaB) and activator protein-1 (AP-1) double inhibitors SP100030 and SP100207 at a dose of 5 mg/kg and 10 mg/kg of body weight, respectively, resulted in a clear inhibition of tumour growth. The decrease was not related to an altered cell cycle distribution of the tumour cell population suggesting a merely necrotic effect. The results presented confirm that both transcription factors are involved in the growth of the experimental tumour system used, suggesting that both signaling cascades play a very important role in the signaling of tumour cell proliferation. This could, in future, allow for the development of new therapeutic strategies for cancer patients.

• Authors: Rodrigo Moore-Carrasco, Sílvia Busquets, Maite Figueras, Moorthy Palanki, Francisco J López-Soriano, Josep M Argilés
• Journal: Anticancer research (Anticancer Res) Vol. 29 Issue 4 Pg. 1315-7 (Apr 2009) ISSN: 0250-7005 [Print] Greece
• PMID: 19414381 (Publication Type: Journal Article)

Chemical References

• Immunosuppressive Agents
• N-(3,5-bis(trifluoromethyl)phenyl)-2-chloro-4-(trifluoromethyl)pyrimidine-5-carboxamide
• NF-kappa B
• Organic Chemicals
• Transcription Factor AP-1

Topics

• Animals
• Flow Cytometry
• Immunosuppressive Agents (pharmacology)
• Liver Neoplasms, Experimental (drug therapy, metabolism, pathology)
• Male
• NF-kappa B (antagonists & inhibitors, physiology)
• Organic Chemicals (pharmacology)
• Rats
• Rats, Wistar
• Transcription Factor AP-1 (antagonists & inhibitors, physiology)